Pharmacopeia

CWP-0167

Midodrine

Cardiovascular · Level 3

Core pharmacology

Class Group

Oral peripheral alpha-1 adrenoceptor agonist prodrug; vasopressor.

Main Action

Increases peripheral vascular resistance and blood pressure without direct beta-adrenergic inotropy.

Mechanism of action

Midodrine is converted to desglymidodrine, an alpha-1 adrenergic agonist that contracts arteriolar and venous vascular smooth muscle.

Indications Uses

Symptomatic orthostatic hypotension in selected patients. ICU use to facilitate liberation from intravenous vasopressors is off-label and is not supported for routine use by the MIDAS randomised trial.

Absorption

Rapid oral absorption; bioavailability of active desglymidodrine about 93%; prodrug peaks at about 30 minutes and active metabolite peaks around 1–2 hours.

Metabolism

Deglycination in multiple tissues converts midodrine to active desglymidodrine; additional metabolism occurs partly in the liver.

Excretion

Active metabolite is eliminated mainly via kidneys, with substantial active tubular secretion; exposure may rise with renal dysfunction.

Half-life

Midodrine prodrug half-life about 25 minutes; active metabolite desglymidodrine about 3–4 hours.

Adverse Effects Toxicity

Supine hypertension (major limiting toxicity), bradycardia, piloerection/scalp pruritus and urinary retention.

Special Points

MIDAS RCT: no reduction in vasopressor discontinuation time; bradycardia was more frequent with midodrine (7.6% vs 0%). Avoid implying proven ICU vasopressor-weaning benefit. Monitor supine blood pressure, heart rate and renal function.

Source references

These October 2026 additions were reconciled against the linked sources. Refer to current local formulary guidance for clinical prescribing.